Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

2.50
+0.11004.60%
Post-market: 2.530.0280+1.12%19:51 EDT
Volume:735.93K
Turnover:1.83M
Market Cap:350.00M
PE:-5.78
High:2.54
Open:2.41
Low:2.35
Close:2.39
52wk High:2.54
52wk Low:1.33
Shares:140.00M
Float Shares:64.52M
Volume Ratio:1.58
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4327
EPS(LYR):-0.4909
ROE:-51.96%
ROA:-32.79%
PB:2.28
PE(LYR):-5.09

Loading ...

Inhibikase Shareholders Approve Governance and Compensation Changes

TIPRANKS
·
Jun 29

Inhibikase Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jun 29

Inhibikase Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating and Target Price $5

THOMSON REUTERS
·
Jun 10

Inhibikase Therapeutics initiated with an Outperform at Oppenheimer

TIPRANKS
·
Jun 10

Oppenheimer Initiates Inhibikase Therapeutics at Outperform

MT Newswires Live
·
Jun 10

Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8

TIPRANKS
·
May 26

LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)

TIPRANKS
·
May 16

Analysts Are Bullish on These Healthcare Stocks: Milestone Scientific (MLSS), Inhibikase Therapeutics (IKT)

TIPRANKS
·
May 15

Inhibikase Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Benzinga Earnings
·
May 13

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

THOMSON REUTERS
·
May 13

Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension

TIPRANKS
·
May 13

Inhibikase Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
May 08

Inhibikase Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 21

Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway

TIPRANKS
·
Apr 09

Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target

TIPRANKS
·
Apr 08

Inhibikase Begins Pivotal Phase 3 Trial in PAH

TIPRANKS
·
Apr 07

Inhibikase enrolls first patient in Phase 3 IMPROVE-PAH trial for IKT-001

Reuters
·
Apr 07

Inhibikase Therapeutics Announces Enrollment of First Patient in Improve-Pah Global Phase 3 Study of Ikt-001 in the Treatment of Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Apr 07

Inhibikase grants 685,718 inducement stock options to five new hires at $1.68/share

Reuters
·
Apr 04